Medtronic (NYSE:MDT) said today that the 1st patient was enrolled in a study of its In.Pact Admiral drug-coated balloon in patients with end-stage renal disease.
The FDA approved the investigational device exemption study to evaluate the device as a treatment for failing arteriovenous fistulas in end-stage renal disease patients.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic launches study of In.Pact Admiral drug-coated balloon in end-stage renal disease appeared first on MassDevice.